The AbbVie pipeline technique, an organization at an inflection level  

Since its spin-out from Abbott in 2013, AbbVie’s pipeline technique has been constructed round a dominant immunology franchise anchored by Humira. For a lot of the previous decade, that system labored very effectively. Humira grew right into a profitable drug, producing greater than $20 billion a yr at its peak and giving AbbVie each scale and monetary flexibility. 

However that success additionally got here with a structural vulnerability. The long-anticipated Humira patent cliff, materializing within the U.S. with the arrival of biosimilars in 2023, has been the defining constraint shaping AbbVie’s technique lately. AbbVie entered this era with a plan already in movement, constructed across the speedy growth of its next-generation immunology medication and a gradual cadence of exterior offers. 

This text appears to be like at AbbVie’s current strikes as a part of a broader pipeline technique. The query will not be merely whether or not AbbVie can offset Humira’s decline, however whether or not it will probably accomplish that with out recreating the identical focus threat, and as an alternative flip its immunology base right into a sturdy money engine together with new pillars in oncology and neuroscience that may stand on their very own. 

The inspiration: securing the post-Humira money engine 

AbbVie’s current pipeline technique solely actually is smart for those who begin with the constraint it has been managing since 2023, Humira’s U.S. erosion as soon as biosimilars arrived. The primary U.S. Humira biosimilar, Amgen’s Amjevita, launched in January 2023, kicking off the aggressive part that AbbVie had spent years getting ready for. AbbVie’s personal reporting exhibits how abrupt that shift grew to become within the U.S.; in its full-year 2024 outcomes, the corporate mentioned U.S. Humira internet revenues fell 54.5% year-on-year, with worldwide gross sales additionally declining. 

Somewhat than attempting to defend Humira indefinitely, AbbVie has leaned right into a transition the place Skyrizi and Rinvoq grow to be the immunology development engine that replaces the hole left behind. AbbVie has been specific about how massive it thinks that engine can get. In January 2025, the corporate raised its long-term outlook, and mentioned it expects mixed Skyrizi and Rinvoq income of greater than $31 billion in 2027, with Skyrizi projected at greater than $20 billion and Rinvoq at greater than $11 billion. 

Strategically, it creates post-patent-cliff predictability. A reputable immunology base offers AbbVie room to put longer bets elsewhere, in different phrases, to purchase platforms, take scientific threat in oncology or neuroscience, and soak up setbacks with out each program being framed as a make-or-break Humira substitute. 

Inside AbbVie’s pipeline: what it has really been shopping for

If AbbVie’s immunology transition is the monetary base, the previous yr or so of enterprise improvement exhibits how the corporate is attempting to construct what comes subsequent. 

The clearest directional sign got here in oncology. In February 2024, AbbVie accomplished its acquisition of ImmunoGen, bringing in Elahere (mirvetuximab soravtansine), an antibody-drug conjugate (ADC) authorized for platinum-resistant ovarian most cancers, together with an ADC pipeline meant to increase past a single product. AbbVie already had an oncology footprint, however shopping for ImmunoGen added a ready-made ADC platform and a industrial anchor that may help follow-on improvement. 

In August 2024, AbbVie closed the Cerevel Therapeutics acquisition, a bigger wager on neuroscience. Cerevel’s portfolio included a number of central nervous system (CNS) packages, with AbbVie highlighting emraclidine, a muscarinic M4 PAM, then transferring by part 2 research for schizophrenia, as a possible flagship. Past any single asset, the deal was about increasing AbbVie’s neuroscience engine into psychiatry and motion problems with late scientific pictures. 

Then, in December 2024, AbbVie doubled down on neurodegeneration through the acquisition of Aliada Therapeutics. AbbVie framed the deal round two elements: ALIA-1758, an anti-pyroglutamate amyloid-beta antibody Alzheimer candidate, and blood-brain barrier supply know-how designed to extend CNS publicity.  

On the immunology facet, AbbVie made a smaller transfer in January 2025 with the completion of its Nimble Therapeutics acquisition. Nimble introduced a preclinical oral peptide IL-23R inhibitor positioned for psoriasis, plus a peptide discovery/screening platform, a wager on oral immunology innovation somewhat than one other injectable biologic. 

Alongside acquisitions, AbbVie has leaned closely on collaborations. In early 2024, it partnered with Tentarix on conditionally lively multispecific biologics in oncology and immunology, structured with upfront possibility funds and the potential to purchase packages later.  

By 2025, AbbVie’s enterprise improvement slowed in headline measurement, with fewer massive acquisitions and a clearer emphasis on selective partnerships and pipeline execution. Somewhat than saying one other platform-scale buyout, the corporate targeted on advancing property it had already introduced in and layering smaller, option-driven offers on prime.  

In oncology, AbbVie continued to broaden the scientific footprint of Epkinly (epcoritamab), its CD20×CD3 bispecific antibody partnered with Genmab, with further information and label expansions along with an approval from the Meals and Drug Administration (FDA) together with rituximab and lenalidomide for relapsed or refractory follicular lymphoma. 

The corporate additionally entered a multi-year collaboration with Neomorph to develop molecular glue degraders in oncology and immunology, and signed an siRNA discovery and improvement settlement with ADARx Prescribed drugs, spanning neuroscience, immunology, and oncology. AbbVie secured an option-based licensing cope with Simcere Zaiming for a trispecific a number of myeloma antibody outdoors China, reinforcing its hematology-oncology pipeline with out taking up full early-stage threat. 

Abbvie’s strategy to oncology: constructing a modality stack, not a single franchise 

The ImmunoGen acquisition is the clearest instance of AbbVie shopping for each income and an engine. First, it offers AbbVie a industrial wedge in strong tumors, not only a pipeline promise. Second, it successfully imports an inside ADC platform at a time when ADCs have grow to be some of the contested battlegrounds in oncology. AbbVie might have had oncology property earlier than, however ImmunoGen gave it a purpose-built ADC footprint somewhat than a scattered set of packages. 

The timing of full FDA approval can be splendid. Immunogen’s Elahere beforehand had accelerated approval, and in March 2024, the FDA granted it full common approval. Shopping for an ADC firm and rapidly holding an asset that clears confirmatory overview consolidates the transfer. 

ADCs are just one leg of AbbVie’s oncology construct. The corporate can be positioning itself in bispecific antibodies, significantly in hematologic malignancies, by Epkinly with Genmab. With an FDA approval in 2025, the modality isn’t redundant with ADCs, it’s complementary. Proudly owning each will increase AbbVie’s odds of constructing sturdy oncology income with out betting every thing on one strategy. 

This strategy additionally matches AbbVie’s historical past. The corporate’s 2015 acquisition of Pharmacyclics was explicitly framed as creating a number one hematological oncology franchise constructed round Imbruvica, then a fast-growing BTK inhibitor with a broad scientific program.  

The distinction now’s that AbbVie is attempting to purchase repeatable modalities, not only a single molecule. For example, ImmunoGen isn’t simply Elahere; it’s an ADC platform. It appears AbbVie’s oncology technique is designed to make sure development isn’t fully reliant on one mechanism or one tumor sort. 

Alzheimer’s: a persistent problem and a cautious return 

For AbbVie, Alzheimer’s has been a illness space the corporate has repeatedly tried to enter, realized from, and, extra just lately, re-entered with a noticeably completely different set of assumptions. 

The primary clear AbbVie chapter in Alzheimer’s R&D was its anti-tau wager. That technique made scientific sense as tau pathology tracks extra intently with cognitive decline than amyloid, and the sector hoped that concentrating on extracellular tau might sluggish illness development. AbbVie’s antibody tilavonemab moved right into a part 2 examine in early Alzheimer’s illness, however the outcomes finally didn’t show efficacy, regardless of being usually effectively tolerated.  

AbbVie then explored further angles, together with amyloid-directed approaches. In mid-2024, the corporate discontinued additional improvement of ABBV-916 as a stand-alone antibody for Alzheimer’s, amid what it described as an “evolving panorama.”  

The corporate additionally skilled setbacks by partnered efforts. In late 2024, Alector’s AL002, an AbbVie-partnered program geared toward modulating microglia biology, failed to fulfill its major endpoint in a part 2 Alzheimer’s trial, displaying once more how unforgiving mid-stage readouts in Alzheimer’s stay. 

AbbVie’s Aliada acquisition in 2024 is likely to be a cautious return on completely different phrases. The headline asset, ALIA-1758, is an early-stage anti-pyroglutamate amyloid-beta antibody, however the strategic hook is Aliada’s blood-brain barrier (BBB) crossing know-how, designed to extend drug supply to the mind. 

Past Alzheimer’s: AbbVie’s neuroscience pipeline technique

AbbVie’s largest non-Alzheimer’s neuroscience swing lately was Cerevel. When the corporate closed the $8.7 billion deal in August 2024, Cerevel supplied a number of scientific pictures throughout psychiatry and neurology. 

AbbVie highlighted emraclidine prominently as a result of it represented a big industrial market and had part 2 research designed to arrange registration-enabling selections. In different phrases, it was the asset that would have made Cerevel really feel like a quick neuroscience win, equally to elahere in oncology. 

Nevertheless, in January 2025, AbbVie disclosed that emraclidine failed in two part 2 schizophrenia research and mentioned it will take an roughly $3.5 billion cost associated to this system. AbbVie had paid for a reputable path to a psychiatry development pillar, and the readout eliminated it from its technique in a single stroke. 

The corporate nonetheless had significant CNS publicity by Cerevel’s Parkinson’s candidate tavapadon, and this system delivered optimistic part 3 topline readouts, giving AbbVie one thing tangible to maintain the neuroscience pillar alive even after schizophrenia collapsed. In September, AbbVie submitted a brand new drug utility to the FDA for the candidate. 

And AbbVie did add to psychiatry once more. In 2025, AbbVie agreed to purchase Gilgamesh for as much as $1.2 billion for its melancholy asset bretisilocin. 

What to look at subsequent in AbbVie’s technique 

Taken collectively, AbbVie’s pipeline technique level to an organization attempting to maneuver previous a blockbuster with out recreating the identical dependency elsewhere. Immunology supplies the money engine, whereas oncology and neuroscience are being constructed by platforms, complementary modalities. 

It’s attention-grabbing to notice that not each wager has labored, however AbbVie has responded successfully as the dealing with of Alzheimer’s setbacks, and the course correction after emraclidine show. On the identical time, AbbVie has not retreated into its consolation zone because it continues to put capital behind differentiated oncology modalities and selectively rebuilds its neuroscience publicity. 

Wanting into 2026, the corporate has lined up a number of regulatory and scientific catalysts, together with ongoing label growth readouts for Rinvoq throughout indications similar to hidradenitis suppurativa, vitiligo and systemic lupus. In neuroscience, AbbVie’s Parkinson’s candidate tavapadon has moved into regulatory overview following optimistic part 3 topline outcomes, with the potential for an FDA determination that might mark a uncommon neurodegenerative approval for the corporate. On the oncology entrance, progress with further ADC candidates similar to pivekimab sunirine (PVEK), presently underneath FDA overview for uncommon blood cancers, might broaden AbbVie’s industrial footprint past Elahere.